Suppr超能文献

氯吡格雷预处理 ST 段抬高型心肌梗死患者对随后普拉格雷负荷后血小板反应性无影响:一项观察性研究中的血小板反应性。

Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.

机构信息

Klinik für Kardiologie und Angiologie II, Universitäts-Herzzentrum Freiburg · Bad Krozingen , Südring 15, , D-79189 Bad Krozingen , Germany.

出版信息

Platelets. 2013;24(7):549-53. doi: 10.3109/09537104.2012.736045. Epub 2012 Dec 5.

Abstract

Current guidelines recommend prasugrel or ticagrelor for patients undergoing percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). Whereas available data support ticagrelor independent of pretreatment with clopidogrel, corresponding data for prasugrel are missing. Here, we investigated platelet reactivity after loading with prasugrel in clopidogrel-naïve vs. clopidogrel-pretreated patients. Forty-seven consecutive patients with STEMI referred for primary PCI were enrolled. Use of GPIIb/IIIa inhibitors and known contraindications to prasugrel served as exclusion criteria. A total of 31 patients were already treated with a loading dose of clopidogrel 600 mg by the emergency medical system before admission, while 16 patients were P2Y12 antagonist naïve. All patients received a loading dose of prasugrel 60 mg immediately before PCI. Adenosine diphosphate (ADP) induced platelet reactivity was determined by VerifyNow™ P2Y12 assay, by light transmission aggregometry (LTA) and by multiple electrode impedance aggregometry (MEIA; Multiplate™ analyser). No differences in platelet reactivity were observed at day 1 after PCI between the bolus-on-bolus treatment regimen and single prasugrel loading. Platelet reactivity was profoundly decreased to 10 [8-31] platelet reactivity unit (PRU; median [interquartile range]) in patients on clopidogrel + prasugrel vs. 9 [6-60] PRU in patients on prasugrel only (p = 0.916). Consistent results were obtained by LTA and MEIA. The proportion of patients reaching a MEIA associated with increased risk bleeding (<188 AU*min) was also similar between the two study groups. The level of platelet reactivity at day 1 after the 60 mg loading dose of prasugrel was independent of pretreatment with clopidogrel. Our results do not support withholding prasugrel in patients pretreated with clopidogrel who undergo PCI for STEMI.

摘要

目前的指南建议在 ST 段抬高型心肌梗死(STEMI)患者行经皮冠状动脉介入治疗(PCI)时使用普拉格雷或替格瑞洛。虽然有数据支持在没有预先使用氯吡格雷的情况下使用替格瑞洛,但缺乏关于普拉格雷的相应数据。在这里,我们研究了在氯吡格雷预处理和未预处理的患者中,负荷剂量普拉格雷后的血小板反应性。

连续纳入 47 例因 STEMI 而接受直接 PCI 的患者。使用 GPIIb/IIIa 抑制剂和已知的普拉格雷禁忌症作为排除标准。共有 31 例患者在入院前已通过急救医疗系统接受了氯吡格雷 600mg 的负荷剂量治疗,而 16 例患者对 P2Y12 拮抗剂一无所知。所有患者在 PCI 前立即接受普拉格雷 60mg 的负荷剂量。

通过 VerifyNow P2Y12 测定法、光传输聚集测定法(LTA)和多电极阻抗聚集测定法(MEIA;Multiplate 分析仪)测定二磷酸腺苷(ADP)诱导的血小板反应性。在 PCI 后第 1 天,与氯吡格雷+普拉格雷的 bolus-on-bolus 治疗方案相比,单剂量普拉格雷负荷的血小板反应性无差异。与仅接受普拉格雷的患者(9 [6-60] PRU)相比,接受氯吡格雷+普拉格雷治疗的患者的血小板反应性显著降低至 10 [8-31] PRU(中位数 [四分位数范围])(p=0.916)。LTA 和 MEIA 也得到了一致的结果。两组患者中达到与增加出血风险相关的 MEIA (<188 AU*min)的患者比例也相似。

接受 60mg 普拉格雷负荷剂量后第 1 天的血小板反应性水平与氯吡格雷预处理无关。我们的研究结果不支持在接受氯吡格雷预处理并接受 PCI 治疗 STEMI 的患者中停用普拉格雷。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验